Skip to main content
. 2024 Nov 27;12(1):e200331. doi: 10.1212/NXI.0000000000200331

Figure 2. Profiling Activated Complement Protein and IgG Levels Along With AChR-Specific Antibody Effector Functions on Treatment Initiation With Ravulizumab and Efgartigimod.

Figure 2

(A) Serum complement C5a and (B) total igG protein levels were quantified at baseline, at 10 weeks after ravulizumab therapy, and 8 weeks after initiation of efgartigimod therapy. Only ravulizumab-treated patients presented with a significant decrease in terminal complement factors C5a (p = 0.00024). Only efgartigimod-treated patients presented with a significant decrease in total IgG levels (p = 0.03). Mean relative difference for total IgG levels in efgartigimod-treated patients is −22.0 and for ravulizumab-treated patients is 8.2. (C) Antibody-dependent complement deposition and (D) phagocytosis induced by isolated AChR-specific IgG quantified at baseline, at 10 weeks after ravulizumab therapy, and 8 weeks after initiation of efgartigimod therapy. Indicated in gray are individual patients. Indicated in red are the median at baseline and median differences for follow-up along with the interquartile range. AChR = acetylcholine receptor; IgG = immunoglobulin G.